艾沙康唑治疗药物监测与不良事件的关联
Youden指数显示血清浓度5.86 µg/mL为毒性风险的阈值,24例减量患者症状均缓解。
要点
- 血清浓度5.86 µg/mL对应毒性风险阈值的灵敏度41.0%、特异度87.1%。
- 24例减量患者症状均缓解。
核心结论
- 艾沙康唑存在暴露-毒性关系,治疗药物监测可能对出现潜在毒性症状者有益。
主要发现
- Youden指数显示血清浓度5.86 µg/mL平衡灵敏度(41.0%)与特异度(87.1%)以判定毒性风险。
- 24例减量患者症状均缓解。
关键数值与推荐
- 血清浓度5.86 µg/mL对应毒性风险判定的灵敏度41.0%、特异度87.1%。
临床怎么用
- 对出现潜在毒性症状的艾沙康唑治疗患者,治疗药物监测可能有益。
- 不良事件归因于艾沙康唑的患者,减量常使症状缓解。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Isavuconazole is efficacious in the treatment of aspergillosis, mucormycosis, and other invasive fungal infections. Therapeutic drug monitoring is generally not assessed during treatment with isavuconazole due to its high oral bioavailability, modest drug-drug interactions, and linear pharmacokinetics. This study aimed to determine whether an exposure-toxicity relationship exists for isavuconazole in those experiencing potential adverse drug events. METHODS: This retrospective study analysed adult outpatients receiving isavuconazole and the occurrence of adverse events. Patients with and without adverse events were compared to identify serum drug concentrations predictive of potential drug-related toxicity. RESULTS: Ninety-five patients, corresponding to 219 serum levels total, were analysed. Thirty-seven (38.9%) developed adverse events, most commonly transaminitis (29.7%), diarrhoea (24.3%), and nausea (18.9%). Using Youden's index, a serum level of 5.86 µg/mL corresponded to a threshold balancing sensitivity (41.0%) and specificity (87.1%) in the determination of toxicity risk. All 24 patients undergoing isavuconazole dose reduction demonstrated resolution of symptoms. CONCLUSIONS: Our findings identified an exposure-toxicity relationship for isavuconazole. Therapeutic drug monitoring may be beneficial for those on isavuconazole therapy who develop signs or symptoms of potential toxicity. Additionally, in patients with adverse events attributed to isavuconazole, dose reduction often led to resolution.
引用
- Huang E, Wittenberg R, Dray JV, et al. Isavuconazole therapeutic drug monitoring and association with adverse events. J Antimicrob Chemother. 2025. PMID: 40289250. doi:10.1093/jac/dkaf128
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。